All News

uveitis eye iritis

New Insights into Uveitis in Spondyloarthritis

d Antoni Chan, MD, PhD

Uveitis is the most frequent extra-musculoskeletal manifestation (EAM) in Axial Spondyloarthritis (axSpA). The prevalence of uveitis in axSpA is between 25-30%. Up to 50% of patients with an acute episode of uveitis develop recurrent anterior uveitis or iritis.

Read Article
lung%2Cbright.jpg

Cytokine Inhibitor Lung Disease in Still's Linked to HLA-DRB1 Alleles

d Jack Cush, MD

Pulmonary complications in the setting of Still's disease (juvenile and adult) has seldom but consistently been reported, including reports of pneumonitis, pulmonary hypertension and a severe or fatal lung disease, often associated with hypersensitivity to anticytokine therapy. A multicenter study reports that drug hypersensitivity and pulmonary reactions in Still's patients receiving IL-1 or IL-6 inhibitors is strongly associated with HLA-DRB1*15 haplotypes.

Read Article
Plaquenil.HCQ_.pills_.jpg (keep)

Prolonging the Controversy of Hydroxychloroquine

d Kathryn H. Dao, M.D.

Since the start of the pandemic, hydroxychloroquine (HCQ) was forced into the limelight for the prevention/treatment of COVID-19. When it was found to be ineffective for COVID-19 and might cause potential harm, the drug came under closer scrutiny for its safety profile.

Read Article
Sle.vote_.criteria.png

DORIS - Defining Remission in Lupus

d Jack Cush, MD

Proponents of treat to target in systemic lupus erythematosus (SLE) have all agreed that "remission" should be the goal, but defining remission may be tricky in SLE.  A SLE Definitions Of Remission (DORIS)Task Force was convened in 2015 and first published their work in 2016.

Read Article
GCA temporal artery

Giant Cell Arteritis Novel Treatment Options

d Richard Conway, MBBChBAO, PhD

Giant cell arteritis is associated with significant treatment related morbidity due to the dependence on glucocorticoids as a treatment option. After sixty years of therapeutic stagnation, these are exciting times in the management of GCA. At this year's ACR Convergence meeting, encouraging data will be presented on options for GCA.

Read Article
Might Tofacitinib Reduce Malignancy Risk with Patients with RA? https://t.co/xDnbPvjFDj https://t.co/yVcftm9Vwz

Links:

Dr. John Cush RheumNow ( View Tweet)
Watch: TNFi in axSpA https://t.co/uS01KNDgIH https://t.co/eb0W3fBKhq

Links:

Dr. John Cush RheumNow ( View Tweet)
Diagnosing (Bad) VEXAS: The Experts Speak Dr. Cush discusses Dr. Marcela Ferrada and Dr. David Beck to discuss VEXAS syndrome and abstract 1426, which was presented at the ACR21 annual meeting. https://t.co/7nncosDjO3 https://t.co/hnltnnMkrm

Links:

Dr. John Cush RheumNow ( View Tweet)
Pediatric Psoriatic Arthritis: Dr. Eric Ruderman ( @JointMD) discusses abstracts #1424 presented at the ACR21 annual meeting. https://t.co/aRCPAlBGev https://t.co/jsa261ZuYx

Links:

Dr. John Cush RheumNow ( View Tweet)
"Doctor, I Can Tell When It's Raining!" Dr. Najm ( @AurelieRheumo) discusses abstract #1912 presented at the ACR21 annual meeting. https://t.co/ZMY0Btmdt1 https://t.co/H9mVnt2Kdi

Links:

Dr. John Cush RheumNow ( View Tweet)
Urine Proteome Advances: What Do They Mean? https://t.co/rfIUThDF93 https://t.co/CcUleDW2aM

Links:

Dr. John Cush RheumNow ( View Tweet)
Medication Preferences in Patients with Psoriatic Arthritis https://t.co/t88Kgn28F7 https://t.co/kVVd4GXd99

Links:

Dr. John Cush RheumNow ( View Tweet)
Guselkemab vs. Ustekinumab in PsA https://t.co/YJ8M3byZg6 https://t.co/wxSpkvnb84

Links:

Dr. John Cush RheumNow ( View Tweet)
Air pollution may induce #RA flares. A Verona, Italy study of 888 pts correlated pollutants to abnormal CRP levels - Pts exposed to greater air pollutant leveles had higher risk of CRP levels ≥5 mg/l; air pollutants were higher in 60d prior to RA flares https://t.co/2ICHdxbqGS https://t.co/QGq6mQals7

Links:

Dr. John Cush RheumNow ( View Tweet)
Pregnancy Outcomes in PsA, SpA, RA: Dr. Rachel Tate ( @uptoTate) reviews abstracts #0369, #1722 and #1730 presented at the ACR21 annual meeting. https://t.co/kUQReWtEdO https://t.co/MZ9Fe1Ms3N

Links:

Dr. John Cush RheumNow ( View Tweet)
Patient Reported Outcomes in axSpA: Dr. Swetha Alexander ( @swethaann23) reviews abstracts #0359, #0357 and #0366 presented at the ACR21 annual meeting. https://t.co/jLJbNgZ7Vd https://t.co/yljOgrSniH

Links:

Dr. John Cush RheumNow ( View Tweet)
Hospitalization Trends in Patients with Psoriatic Arthritis: Dr. Olga Petryna discusses abstract #1783 presented at the ACR21 annual meeting. https://t.co/7xSb7l2Rfw
Dr. John Cush RheumNow ( View Tweet)
444 Bio-IR or csDMARD-IR #PsA pts were Rx w/ anti-IL-23, risankizumab 150 mg Sc vs PBO at Wks 0, 4, 16, @wk 24 RIZ had significantly better ACR20 resp (51% vs 26%, p<0.001). No differences in SAE (4 vs 5.5%) or SIE (0.9% vs 2.3%). https://t.co/os2AMgG4kc

Links:

Dr. John Cush RheumNow ( View Tweet)

Drs. Jack Cush and Drs. Akhil Sood, Antoni Chan, Olga Petryna and Eric Dein, discuss highlights from Day 3 at the ACR21 annual meeting. Abstracts include #1367, #1044, #1444, #1083 and more. @akhilsoodsood @synovialjoints @DrPetryna @ejdein1 https://t.co/5lioAkgg2h https://t.co/YReoAepKw1

Links:

Dr. John Cush RheumNow ( View Tweet)
Cardiovascular Disease for TNFi vs JAKi: Dr Jon Giles discusses abstracts #0831and #0958 presented at the ACR21 annual meeting. https://t.co/O90HInaS7z https://t.co/MdHVyxfkaW

Links:

Dr. John Cush RheumNow ( View Tweet)
×